Forskolin, a naturally occurring activator of adenylate cyclase, inhibits total and high-affinity cyclic AMP phosphodiesterase activity in soluble and particulate fractions of cultured LLC-PK1 renal epithelial cells. The naturally occurring forskolin analogue 1,9-dideoxyforskolin, which does not stimulate adenylate cyclase activity, is a more potent inhibitor of cyclic AMP phosphodiesterase activity than forskolin. To clarify the structural feature of the forskolin molecule responsible for inhibition of cyclic AMP phosphodiesterase activity, the effects of two agents which share structural identity with portions of the forskolin ring were tested. The steroid 5-pregnenolone, but not the hexose a-Dgalactose, inhibited cyclic AMP phosphodiesterase activity in LLC-PK1 cells. Forskolin and 1,9-dideoxyforskolin both stimulate protein kinase C activity in LLC-PK1 cells. The effect of 1,9-dideoxyforskolin in stimulating LLC-PK1 protein kinase C activity can be attenuated by staurosporine. Both 5-pregnenolone and a-D-galactose also stimulate protein kinase C activity in LLC-PK1 cells. 5-Pregnenolone and the phorbol ester phorbol 12-myristate 13-acetate cause translocation of protein kinase C from a soluble to a particulate fraction, while both 1,9-dideoxyforskolin and a-D-galactose increase protein kinase C activity in both soluble and particulate fractions. Our results demonstrate that forskolin exerts diverse enzymic effects in cultured LLC-PK1 cells.
INTRODUCTION
Forskolin is a unique diterpene found in extracts of the root of the coleus plant [1] . It was first described in 1981 as a cardioactive substance that reversibly increases adenylate cyclase activity in vivo and in vitro [1] . Subsequently, forskolin has been widely utilized as a pharmacological probe in biochemical studies in which it is thought to directly activate the catalytic subunit of adenylate cyclase [1] . However, recent studies indicate that forskolin not only stimulates adenylate cyclase activity but also exerts adenylate cyclase-independent actions, such as interacting with a glucose transporter, regulating ion channel activity and stimulating cyclic GMP accumulation [1] [2] [3] [4] [5] .
In the present paper, we demonstrate that forskolin and its naturally occurring analogue 1,9-dideoxyforskolin significantly influence cyclic AMP phosphodiesterase and protein kinase C activity in cultured LLC-PK1 cells. Since 1,9-dideoxyforskolin does not stimulate adenylate cyclase activity, these results suggest that forskolin can regulate diverse enzyme systems independent of cyclic AMP. Our results also indicate that both the steroidal ring structure and their structural identity with hexoses may underlie the actions of forskolin and 1,9-dideoxyforskolin in regulating cyclic AMP phosphodiesterase and protein kinase C activities.
MATERIAL AND METHODS

Materials
Forskolin, 1 ,9-dideoxyforskolin and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Calbiochem. Sigma was the source of 4-phorbol 12-myristate 13- Culture conditions and cell fraction preparation Cells were grown in RPMI 1640 medium (Irvine Scientific) supplemented with 20 mg of Na2CO3/ml, 16 mM-Hepes, 100 units of penicillin/ml and 100 ,ug of streptomycin/ml. Newborn calf serum (6 %) was added to the media for the initial 3-7 days of growth, after which all cultures received serum-free medium.
Cultures were maintained at 37 "C in a humidified atmosphere of air/CO2 (19: 1). Confluent growth was usually observed in [5] [6] [7] days.
For adenylate cyclase assays, a crude membrane preparation was obtained from confluent cultures. Cultures were washed with 3 x 8 ml of cold phosphate-buffered saline containing 0.9 mmCaCI2 and 0.5 mM-MgCl2. Cells were harvested by scraping into 4 ml of cold EDTA (1 mM)/Tris (50 mM) buffer (pH 7.4). Membranes were homogenized with 15 strokes of a Dounce homogenizer, centrifuged at 43 000 g at 4 "C for 5 min and resuspended in 500 1l of EDTA/Tris buffer.
For cyclic AMP phosphodiesterase assays, cells were harvested and membranes prepared as described above. For studies on the soluble fraction, membranes were removed by centrifugation at 32 500 rev./min (100000 g) for 30 min.
For protein kinase C assays, cells were harvested as described and sonicated for 2 x 15 s at the minimum output of a Bronson W185 sonicator. The sonicate was centrifuged at 10OOg for 10min to pellet debris and nuclei, and the supernatant was subjected to ultracentrifugation for 60 min at 100 000 g to obtain a soluble fraction. The particulate fraction was resuspended in 1 ml of buffer containing 0.1 % Triton X-100, sonicated as above and centrifuged for 60min at 100000g. The supernatant was used to assay for protein kinase C in the particulate fraction. 
RESULTS
In initial studies the effects of IBMX and forskolin on cyclic AMP phosphodiesterase activity was measured (Table 1 ). These studies demonstrated that high concentrations of forskolin could inhibit cyclic AMP phosphodiesterase activity. We next examined the effects of a wide range of concentrations of forskolin on cyclic AMP phosphodiesterase activity (Figs. 1 and 2 ). In these studies we also measured the effect of 1,9-dideoxyforskolin to determine if the effect of forskolin in inhibiting cyclic AMP phosphodiesterase activity is dependent upon stimulation of adenylate cyclase activity (Figs. 1-3) . These results indicate that the 1,9-dideoxy analogue offorskolin does not promote adenylate cyclase activity, but is a more potent inhibitor of cyclic AMP phosphodiesterase activity than forskolin. Additional studies were done to examine the effects of lower concentrations of forskolin and 1,9-dideoxyforskolin on cyclic AMP phosphodiesterase activity. At 0. and nm, forskolin did not significantly change either total or high-affinity cyclic AMP phosphodiesterase activity in either the particulate or the soluble fraction from LLC-PK1 cells (n = 3). By contrast, I and 10 nM-l,9-dideoxyforskolin significantly decreased membrane (40-50 %) and soluble (35-40 %) forms of both high-affinity and total cyclic AMP phosphodiesterase activities from LLC-PK1 cells (n = 4). Additional studies were undertaken to better delineate the structural feature of forskolin and its 1,9-dideoxy analogue responsible for inhibition of cyclic AMP phosphodiesterase activity. Since forskolin bears structural identity with a number of steroids and with a-D-galactose [2] , the effects of 5-pregnenolone sulphate and a-D-galactose on cyclic AMP phosphodiesterase were measured ( Table 1 ). The steroid 5-pregnenolone, but not a-D-galactose, inhibited cyclic AMP phosphodiesterase activity.
Recently we found that forskolin and soluble cyclic AMP analogues increase protein kinase C activity in LLC-PK1 cells [1O]. To determine if the effect of forskolin in stimulating protein kinase C activity is cyclic AMP-dependent, we examined the effect of l,9-dideoxyforskolin on protein kinase C activity (Fig.  4) . At concentrations greater than 1O nM, 1,9-dideoxyforskolin modestly increased protein kinase C activity. The effect of 1,9-dideoxyforskolin in increasing protein kinase C activity was associated with an increase in enzyme activity in both the soluble and the particulate cell fractions. We next examined the effect of staurosporine, a protein kinase C antagonist, on PMA-and 1,9-dideoxyforskolin-stimulated protein kinase C activity. In these studies (Table 2) , staurosporine completely prevented stimulation of protein kinase C activity by PMA and attenuated the stimulatory effect of 1,9-dideoxyforskolin on protein kinase C activity.
To better delineate the structural features of 1,9-dideoxyforskolin responsible for activation of protein kinase C, we compared the effects of PMA, 1,9-dideoxyforskolin, 5- Vol. 279 pregnenolone and a-D-galactose on LLC-PK, protein kinase C activity (Table 3 ). All compounds increased protein kinase C activity relative to the control. PMA and 5-pregnenolone clearly translocated enzyme activity from a soluble to a particulate fraction, while 1,9-dideoxyforskolin and ac-D-galactose increased activity without translocation. Q. , ,le Table 3 . Effects of PMA, 5-pregnenolone, a-D-galactose and 1,9-dideoxyforskolin on LLC-PK1 cell protein kinase C activity Intact cells were exposed to PMA (0.1 Mm), 5-pregnenolone sulphate (0.1 mM), a-D-galactose (0.1 mM) or 2,9-dideoxyforskolin (0.1 mM) for 5 
DISCUSSION
The results of the present studies suggest that forskolin, particularly at high concentrations, is capable of inhibiting cyclic AMP phosphodiesterase activity in LLC-PK1 cells. These results confirm and extend observations made several years ago that forskolin can inhibit cyclic AMP phosphodiesterase activity [11] . The naturally occurring 1,9-dideoxy analogue of forskolin is nearly devoid of ability to stimulate adenylate cyclase, but inhibits cyclic AMP phosphodiesterase activity to a greater extent than does forskolin. Together, these observations suggest that the regulatory effects of l,9-dideoxyforskolin on cyclic AMP phosphodiesterase activity occurs by a cyclic AMP-independent mechanism. Our results also suggest that the steroidal ring structure may underlie the inhibiting effects of forskolin and its 1,9-dideoxy analogue on cyclic AMP phosphodiesterase activity. Thus 5-pregnenolone sulphate, which shares striking structural identity with forskolin, also inhibits LLC-PK1 cell cyclic AMP phosphodiesterase activity.
Most tissues, including LLC-PK1 cells [12] [5] , and cyclic GMP can regulate activity of some cyclic AMP phosphodiesterases. We found, however, that 8-bromo cyclic GMP stimulated rather than inhibited cyclic AMP phosphodiesterase activity in our LLC-PK1 cells, suggesting that forskolin and 1 ,9-dideoxyforskolin do not regulate cyclic AMP phosphodiesterase activity in LLC-PK1 cells by altering cyclic GMP formation. Further studies are necessary to determine the specific type of LLC-PK1 cell cyclic AMP phosphodiesterase regulated by forskolin, as well as the mechanism of this regulation.
In contrast with our and other results, Grant et al. [13] recently found that treatment of intact human platelets with forskolin (100 /M) increased a high-affinity form of cyclic AMP phosphodiesterase activity in freeze-thawed lysates. This effect of forskolin could be partially blocked by a putative protein kinase inhibitor (H-8) and was associated with phosphorylation of the cyclic AMP phosphodiesterase enzyme [13] . From these results, the authors concluded that forskolin stimulates formation of a cyclic AMP-dependent protein kinase which phosphorylates a high-affinity form of cyclic AMP phosphodiesterase, thereby increasing its catalytic activity. Together, the results of the present and other studies thus suggest that forskolin is capable of regulating cyclic AMP phosphodiesterase activity in both a positive and negative fashion [11, 13] .
Our results also suggest that forskolin and its 1,9-dideoxy analogue are capable of stimulating protein kinase C activity in LLC-PK1 cells [10] . The effect of l,9-dideoxyforskolin in promoting protein kinase C activity differs from that observed with PMA, inasmuch as 1,9-dideoxyforskolin does not cause translocation of enzyme activity. Pregnenolone sulphate and a-Dgalactose, which share structural identity with portions of the forskolin molecule, also promote protein kinase C activity. However, a-D-galactose more closely mimics the effect of 1,9-dideoxyforskolin, inasmuch as it increases total protein kinase C activity without causing translocation of the site of enzyme activity. Glucose has been demonstrated to increase protein kinase C activity in cultured bovine retinal capillary endothelial cells [14, 15] , rat islet of Langerhans cells [16] and rat glomerular cells [17] . Together with the present studies, these observations suggest a role for hexoses in regulation of protein kinase C activity in diverse cell types.
In summary, the present studies demonstrate that forskolin and its 1,9-dideoxy analogue are capable of inhibiting cyclic AMP phosphodiesterase activity and stimulating protein kinase C activity in cultured LLC-PK1 renal epithelial cells. Together with other reports [2] [3] [4] [5] , these observations suggest that forskolin can potentially exert diverse enzymic effects in addition to directly stimulating, the catalytic subunit of adenylate cyclase. The potential capacity of forskolin to simultaneously stimulate the accumulation of two major intracellular second messengers demands caution in interpretation of studies that utilize forskolin as a pharmacological probe.
